Joaquin Duato, J&J CEO (Amir Hamja/Bloomberg via Getty Images)
November 30, 2023 03:10 PM EST
Deals
Pharma

J&J ac­quires Cal­i­for­nia med­ical de­vice com­pa­ny for $400M

Nicole DeFeudis

Editor

John­son & John­son put down $400 mil­lion up­front to ac­quire Lam­i­nar, a med­ical de­vice com­pa­ny fo­cused on re­duc­ing the risk of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times